"First, you need to get the patients into remission or they die of proliferative disease. We are seeing with 29% combined CR rate, the vast majority of these have been full CRs. That’s nearly double, what historical data would say with cytarabine alone. So that’s important.
Giving more patients the chance to respond, those who respond are doing very well. We have a leukemia free survival of two years. That’s driven in part by two-thirds of the CR patients being able to bridge two stem-cell transplants which is a potentially curative therapy balanced with a very low induction mortality of 3%.
So these patients will become neutropenic. Many will have sepsis and other infections when their blood counts are low. But if you can manage them through that successfully without other end organ toxicities, these physicians are used to doing so and you can see that with these mortality rates. So that in and of itself all translates to what was the best data we’ve seen in these type of patient population with a seven-month median overall survival.
So one other area that we explored Vosaroxin and while we have no current company sponsored trial, we do have some investigators sponsored initiative. The follow-up on our very large phase 2 studies, so we conducted while we were doing that phase 2 data, I share with you a parallel study with elderly patients who have multiple risk factors, who are not candidates for standard cytarabine therapy.
You can -- now this is a disease of the elderly and for frail elderly patients. Probably about a third of the patients who are coming -- who are being diagnosed for AML, they are not getting standard induction therapy and there is very much of an unmet medical need.
Importantly, we dose optimized again, this is all single agent data, so real proof-of-concept that vosaroxin is very active in this population and we had an overall CR rate of 32%. Importantly, a one-year survival, these are not candidates for stem cell transplant ..."